新生儿胆汁淤积症胆汁酸转运体和转录调控的研究进展

doi:10.3969/j.issn.1000-8535.2023.04.019

摘要/Abstract

摘要： 新生儿引起肝内胆汁淤积是由感染、遗传代谢性疾病、胃肠外营养、基因突变等各种不同病因导致胆汁形成、分泌和排泄障碍。胆汁在体内淤积会影响新生儿的生长发育,严重者出现肝纤维化、肝功能衰竭等不可逆的改变,其发病的机制涉及参与肝脏胆汁酸分泌的各种转运体、肝细胞膜转运蛋白转录和和转录后的调控等。本文归纳总结近年来国内外关于胆汁酸转运体及其转录和转录后的调控,从而为此疾病的防治提供理论依据,为将来降低其发生率和改善预后。

关键词: 胆汁淤积, 转运体, 生物机制, 转录调控

Abstract: Neonatal intrahepatic cholestasis is caused by infection,genetic metabolic diseases,parenteral nutrition,gene mutation and other different causes leading to bile formation,secretion and excretion disorders．Bile stasis in the body will affect the growth and development of the newborn,and in severe cases,irreversible changes such as liver fibrosis and liver failure will occur．The pathogenesis of bile stasis involves various transporters involved in the secretion of bile acids in the liver,transcription and post transcription regulation of liver cell membrane transporters．In this paper,we summarized the recent studies on bile acid transporters and their transcriptional and post transcriptional regulation at home and abroad,so as to provide a theoretical basis for the prevention and treatment of this disease,and to reduce its incidence and improve its prognosis in the future.

Key words: cholestasis, transporter, biological mechanism, transcriptional regulation

宾淑铭, 杨秀芳. 新生儿胆汁淤积症胆汁酸转运体和转录调控的研究进展[J]. 广州医药, 2023, 54(4): 104-109.

BIN Shuming, YANG Xiufang. Research progress of bile acid transporters and transcriptional regulation in neonatal cholestasis[J]. Guangzhou Medical Journal, 2023, 54(4): 104-109.

参考文献

[1] 陆伦根,蔡晓波,王建设,等.胆汁淤积性肝病管理指南(2021)[J].临床肝胆病杂志,2022,38(1):62-69.
[2] MOYER V,FREESE D K,WHITINGTON P F,et al.Guideline for the evaluation of cholestatic jaundice in infants:recommendations of the North American Society for Pediatric Gastroenterology,Hepatology and Nutrition[J].J Pediatr Gastroenterol Nutr,2004,39(2):115-128.
[3] 赵阳,王建华,胡晓明,等.128例新生儿胆汁淤积症临床病例特征回顾性分析[J].中华临床医师杂志(电子版),2019,13(5):321-325.
[4] 刘笑,王琰.胆汁酸的合成调控及其在生理与病理中的功能机制[J].遗传,2019,41(5):365-374.
[5] 李晓峰,龚敬宇,王建设.胆汁酸的肠肝循环与胆汁淤积性肝病[J].临床肝胆病杂志,2017,33(10):1922-1927.
[6] LU X,LIU L,SHAN W,et al.The role of the sodium-taurocholate co-transporting polypeptide(NTCP)and bile salt export pump(BSEP)in related liver disease[J].Curr Drug Metab,2019,20(5):377-389.
[7] DENG L J,OUYANG W X,LIU R,et al.Clinical characterization of NTCP deficiency in paediatric patients :A case-control study based on SLC10A1 genotyping analysis[J].Liver Int,2021,41(11):2720-2728.
[8] TOTH B,JANI M,BEERY E,et al.Human OATP1B1(SLCO1B1)transports sulfated bile acids and bile salts with particular efficiency[J].Toxicol In Vitro,2018(52):189-194.
[9] SUGA T,YAMAGUCHI H,SATO T,et al.Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3[J].PLoS One,2017,12(1):e0169719.
[10] STICOVA E,LODEREROVA A,van de STEEG E,et al.Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis[J].Int J Clin Exp Pathol,2015,8(5):5252-5262.
[11] 田媛媛,刘梅,熊晶晶,等.ABCB11基因突变致暂时性新生儿胆汁淤积症1例病例报告[J].中国循证儿科杂志,2019,14(2):149-151.
[12] 曹敏玲. 青少年ABCB11基因突变相关肝内胆汁淤积症临床特征分析[J].中国优生与遗传杂志,2021,29(12):1730-1734.
[13] MORAIS M B,MACHADO M V.Benign inheritable disorders of bilirubin metabolism manifested by conjugated hyperbilirubinemia-A narrative review[J].United European Gastroenterol J,2022,10(7):745-753.
[14] CAREY A N,ZHANG W,SETCHELL K D R,et al.Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates[J].Pediatr Res,2017,82(1):122-32.
[15] HEGADE V S,JONES D E,HIRSCHFIELD G M.Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis[J].Dig Dis,2017,35(3):267-274.
[16] MIETHKE A G,ZHANG W,SIMMONS J,et al.Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice[J].Hepatology,2016,63(2):512-523.
[17] PABLO ARAB J,CABRERA D,ARRESE M.Bile acids in cholestasis and its treatment[J].Annals of Hepatology,2017,16(Suppl 1):S53-S57.
[18] CHOTHE P P,CZUBA L C,AYEWOH E N,et al.Tyrosine phosphorylation regulates plasma membrane expression and stability of the human bile acid transporter ASBT(SLC10A2)[J].Mol Pharm,2019,16(8):3569-3576.
[19] ANNABA F,SARWAR Z,GILL R K,et al.Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT[J].Am J Physiol Gastrointest Liver Physiol,2012,302(10):G1216-1222.
[20] LI M,WANG Q,LI Y,et al.Apical sodium-dependent bile acid transporter,drug target for bile acid related diseases and delivery target for prodrugs:Current and future challenges[J].Pharmacol Ther,2020(212):107539.
[21] GAO E,CHEEMA H,WAHEED N,et al.Organic solute transporter alpha deficiency:a disorder with cholestasis,liver fibrosis,and congenital diarrhea[J].Hepatology,2020,71(5):1879-1882.
[22] SULTAN M,RAO A,ELPELEG O,et al.Organic solute transporter-beta(SLC51B)deficiency in two brothers with congenital diarrhea and features of cholestasis[J].Hepatology,2018,68(2):590-598.
[23] MOLINARO A,MARSCHALL H U.Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders[J].Biochem Soc Trans,2022,50(1):361-373.
[24] MEMON N,GRIFFIN I J,LEE C W,et al.Developmental regulation of the gut-liver(FGF19-CYP7A1)axis in neonates[J].J Matern Fetal Neonatal Med,2020,33(6):987-992.
[25] WICHMAN B E,NILSON J,GOVINDAN S,et al.Beyond lipids:Novel mechanisms for parenteral nutrition-associated liver disease[J].Nutr Clin Pract,2022,37(2):265-273.
[26] ZHU Y,LI F,GUO G L.Tissue-specific function of farnesoid X receptor in liver and intestine[J].Pharmacol Res,2011,63(4):259-265.
[27] XIAO Y,ZHOU K,LU Y,et al.Administration of antibiotics contributes to cholestasis in pediatric patients with intestinal failure via the alteration of FXR signaling[J].Exp Mol Med,2018,50(12):1-14.
[28] THIBAUT M M,BINDELS L B.Crosstalk between bile acid-activated receptors and microbiome in entero-hepatic inflammation[J].Trends Mol Med,2022,28(3):223-336.
[29] STERN S,KURIAN R,WANG H.Clinical relevance of the constitutive androstane receptor[J].Drug Metab Dispos,2022,50(7):1010-1018.
[30] GABBIA D,POZZA A D,ALBERTONI L,et al.Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis[J].World J Gastroenterol,2017,23(42):7519-7530.
[31] GONZALEZ-SANCHEZ E,EL MOURABIT H,JAGER M,et al.Cholangiopathy aggravation is caused by VDR ablation and alleviated by VDR-independent vitamin D signaling in ABCB4 knockout mice[J].Biochim Biophys Acta Mol Basis Dis,2021,1867(4):166067.
[32] CHOW E C,MAGOMEDOVA L,QUACH H P,et al.Vitamin D receptor activation down-regulates the small heterodimer partner and increases CYP7A1 to lower cholesterol[J].Gastroenterology,2014,146(4):1048-1059.
[33] SHIH D Q,BUSSEN M,SEHAYEK E,et al.Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabo lism[J].Nat Genet,2001,27(4):375-382.
[34] CHIANG J Y.Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism[J].Expert Opin Drug Metab Toxicol,2009,5(2):137-147.